British national newspaper The Times reported on Thursday that senior sources in the British government expect that a verdict on whether US pharmaceutical company Pfizer Inc's (NYSE:PFE) COVID-19 vaccine works, will be available before the results are in on British pharmaceutical company AstraZeneca Plc's (STO:AZN)(LON:AZN) competing vaccine.
The Times report said that Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas.
Reportedly, Pfizer's Chief Executive, Albert Bourla, had previously said the company could release data on whether or not the vaccine works as early as October 2020.
Pfizer had said this week if trials are successful the company expects to file for emergency authorisation of the vaccine candidate from US regulators shortly after it has enough safety data in late November 2020.
According to Reuters news agency, Britain has supply deals for six vaccine candidates, including frontrunners from Pfizer and AstraZeneca.
EpiVax introduces AI-enhanced models for immunogenicity prediction
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Piramal Pharma acquires controlling stake in Yapan Bio
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070